|
gptkbp:instance_of
|
gptkb:Company
|
|
gptkbp:bfsLayer
|
2
|
|
gptkbp:bfsParent
|
gptkb:physicist
|
|
gptkbp:acquired
|
gptkb:Allergan
gptkb:Imbruvica
|
|
gptkbp:acquisition
|
gptkb:Allergan
gptkb:Stemcentrx
Pharmacyclics (2015)
Allergan's assets
Allergan (2020)
Mavenclad (2019)
Stemcentrx (2016)
|
|
gptkbp:awards
|
gptkb:Fortune_500
gptkb:Diversity_Inc_Top_50
Best Places to Work
Fortune 500 company
Top Employers
Human Rights Campaign Corporate Equality Index
|
|
gptkbp:ceo
|
gptkb:Richard_A._Gonzalez
gptkb:Richard_Gonzalez
|
|
gptkbp:clinical_trial
|
Phase 3 trials
global presence
therapeutic areas
Phase 1 trials
Phase 2 trials
Phase 3 trials for various drugs
patient-centric approach
|
|
gptkbp:competitors
|
gptkb:Johnson_&_Johnson
gptkb:Bristol-Myers_Squibb
gptkb:Pfizer
gptkb:Merck_&_Co.
gptkb:Roche
|
|
gptkbp:developed_by
|
gptkb:drug
|
|
gptkbp:employees
|
approximately 50,000
|
|
gptkbp:faction
|
$6 billion (2022)
|
|
gptkbp:focus
|
Biopharmaceuticals
biopharmaceuticals
immunology
|
|
gptkbp:focuses_on
|
biopharmaceuticals
|
|
gptkbp:founded
|
gptkb:2013
|
|
gptkbp:founder
|
gptkb:Richard_A._Gonzalez
|
|
gptkbp:global_presence
|
operations in over 75 countries
|
|
gptkbp:headquarters
|
gptkb:North_Chicago
gptkb:North_Chicago,_Illinois
|
|
https://www.w3.org/2000/01/rdf-schema#label
|
Abb Vie
|
|
gptkbp:industry
|
gptkb:drug
Pharmaceuticals
|
|
gptkbp:innovation
|
gptkb:physicist
gptkb:drug
biologics
small molecules
|
|
gptkbp:invention
|
numerous patents in oncology
numerous patents in immunology
numerous patents in neuroscience
numerous patents in virology
|
|
gptkbp:known_for
|
gptkb:healthcare_organization
Aesthetics
Immunology
Neuroscience
Virology
|
|
gptkbp:market
|
global pharmaceutical market
|
|
gptkbp:market_cap
|
$200 billion (2022)
|
|
gptkbp:notable_products
|
gptkb:Humira
gptkb:Skyrizi
gptkb:Imbruvica
|
|
gptkbp:part_of
|
gptkb:S&_P_500
|
|
gptkbp:partnership
|
gptkb:Johnson_&_Johnson
gptkb:healthcare_organization
gptkb:Bristol-Myers_Squibb
gptkb:Duke_University
gptkb:Harvard_University
gptkb:University_of_California,_San_Francisco
gptkb:University_of_Chicago
gptkb:Neurocrine_Biosciences
gptkb:Pfizer
gptkb:Amgen
gptkb:Gilead_Sciences
|
|
gptkbp:philanthropy
|
gptkb:Abb_Vie_Foundation
support for health initiatives
support for community development
support for education initiatives
|
|
gptkbp:products
|
gptkb:Humira
gptkb:Venclexta
gptkb:Imbruvica
|
|
gptkbp:research
|
Michael Severino
|
|
gptkbp:research_areas
|
Immunology
oncology
neuroscience
immunology
virology
|
|
gptkbp:research_focus
|
oncology
neuroscience
immunology
virology
|
|
gptkbp:revenue
|
approximately $58 billion (2022)
approximately $56 billion (2022)
$56.1 billion (2022)
|
|
gptkbp:subsidiary
|
gptkb:Abb_Vie_Biotherapeutics
gptkb:Abb_Vie_Deutschland_Gmb_H
gptkb:Abb_Vie_S.r.l.
gptkb:Allergan
|
|
gptkbp:sustainability
|
community engagement
diversity and inclusion
environmental initiatives
|
|
gptkbp:sustainability_initiatives
|
diversity and inclusion programs
supply chain sustainability
employee engagement programs
environmental responsibility initiatives
|
|
gptkbp:symbol
|
gptkb:ABBV
|
|
gptkbp:traded_on
|
gptkb:NYSE
|
|
gptkbp:type
|
gptkb:Company
|
|
gptkbp:website
|
abbvie.com
www.abbvie.com
|